Shares of BrainStorm Cell Therapeutics Inc. (NASDAQ:BCLI) traded up 2% on Monday . The stock traded as high as $2.59 and last traded at $2.53, with a volume of 115,344 shares traded. The stock had previously closed at $2.48.

Separately, Maxim Group reissued a “buy” rating and set a $5.00 price objective on shares of BrainStorm Cell Therapeutics in a report on Saturday, June 4th.

The firm has a 50 day moving average of $2.54 and a 200 day moving average of $2.43. The stock’s market capitalization is $47.38 million.

BrainStorm Cell Therapeutics (NASDAQ:BCLI) last posted its quarterly earnings data on Thursday, August 11th. The biotechnology company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.18) by $0.13. Equities analysts anticipate that BrainStorm Cell Therapeutics Inc. will post ($0.34) earnings per share for the current fiscal year.

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.